YL Biologics, the joint venture between Lupin’s Kyowa subsidiary and Yoshindo founded in 2014, has submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its YLB113 etanercept. YL is seeking a marketing authorisation for treating moderate to severe rheumatoid arthritis and juvenile idiopathic arthritis.
YL Biologics, the joint venture between Lupin’s Kyowa subsidiary and Yoshindo founded in 2014, has submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its YLB113 etanercept. YL is seeking a marketing authorisation for treating moderate to severe rheumatoid arthritis and juvenile idiopathic arthritis.
“This application marks the first biosimilar developed as part of the joint venture between Lupin and Yoshindo,” pointed out YL’s...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
